Dr Ryan Courtney - Cytisine versus varenicline for smoking cessation: A single-blind randomised controlled non-inferiority clinical trial

Dr Ryan Courtney
Date Published:
9 May 2019
Contact person:
Event date: 
Thursday, 9 May 2019 - 3:00pm

Cytisine versus varenicline for smoking cessation aims to evaluate the cost-effectiveness of cytisine compared to varenicline to inform Australian and international health agencies. This presentation will provide an update on the progress of the clinical trial.

Cytisine is a well-tolerated smoking cessation treatment that is superior to placebo and nicotine replacement therapy. Like varenicline, cytisine is a nicotinic acetylcholine receptor partial agonist, yet has never been formally compared against varenicline.

Cytisine has the lowest cost per quality-adjusted-life-year of all smoking cessation medications, and modelling suggests cytisine may be more cost-effective than varenicline.

Findings from the Cytisine versus varenicline for smoking cessation trial are vital for informing policy makers around the world, given the opportunity for significant health-care system savings, particularly for low- and middle-income countries where the majority of cessation medications are cost-prohibitive.

Speaker bio:

Dr Ryan Courtney, Senior Research Fellow and NHMRC Career Development Fellow, National Drug and Alcohol Research Centre (NDARC)

Dr Courtney leads the Tobacco Research Group at NDARC, UNSW Sydney and is a clinical trialist with expertise in smoking cessation and social disadvantage research.

Open to: 
Lecture Room 122, Building R1, 22 - 32 King St Randwick, NSW 2031
Booking deadline: 
Contact for bookings: 
Number of seats available: 
Contact for inquiries: